Maximo Agustin Schiavone: What Does ‘Risk-Factor-Free MI’ Really Mean in Practice?
Maximo Agustin Schiavone, Head of Clinical Research – Bariatric and Metabolic Surgery Department at Hospital Universitario Austral, shared a post on LinkedIn about a recent article by Daniel G. Brieger et al, published in Atherosclerosis:
“A ‘risk-factor-free’ heart attack is one of the most uncomfortable truths in preventive cardiology.
Because it exposes a category error we keep making: we treat risk factors as if they were the disease. But the disease is coronary atherosclerosis—and it can be present, active, and dangerous even when the usual checklist looks ‘clean.’
This review puts numbers on it: 14–25% of MI patients present without standard modifiable risk factors (SMuRFs), and SMuRFs explain only ~53–56% of incident CVD events globally. And the inequity signal is loud: SMuRF-less women with MI have nearly a threefold higher early mortality risk compared with men who have at least one risk factor.
So what does ‘risk-factor-free MI’ really mean in practice?
It often means ‘we missed the atherosclerosis’—because our prevention model is built to estimate risk, not to detect disease. The authors explicitly argue for moving beyond probability scores to directly detect the causal disease (atherosclerosis) before symptoms arise.
That framing matters: if you’re ‘SMuRF-less’ the correct clinical reflex shouldn’t be reassurance. It should be better phenotyping and a pathway that stops confusing ‘absence of classic risk factors’ with ‘absence of coronary disease.’
And yes, sex needs to be treated as a biological variable in the whole pipeline, because the performance gaps are most evident in women.”
Title: Coronary artery disease in the absence of standard modifiable risk factors (SMuRFs): The impact of sex
Authors: James Amamoo, Lin Xie, Andrea Steffens, Erin Buysman, Caroline Swift, Sherif Mehanna, Noelle N. Gronroos, Marc P. Bonaca
Read the Full Article on Atherosclerosis
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 05:17Maxime Dely: When ABO Compatibility Isn’t Enough for Safe Transfusion
-
Sep 20, 2026, 04:54William Aird: What Does a Complete History and Physical Really Mean?
-
Sep 20, 2026, 04:34Hons Saurabh Kaushik: Why Uncontrolled LDL Can Be Harmful
-
Sep 20, 2026, 03:58Salih Ehsan: The Complexities of HbF and HbA2
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy